Bill Gleim, formerly of ConsenSys, will lead technology team for the new life sciences and healthcare spin-off ConsenSys Health
New York, NY, February 27—ConsenSys Health announced today that Bill Gleim, M.Sc., will be its Chief Technology Officer, leading the technology strategy and team. Mr. Gleim will lead the technological strategy and productization of next-generation privacy-in-depth computation infrastructure. A key element of this strategy is public contributions to the ecosystem, including production-readiness assessment tools and source code.
“Bill is perfect for this role given his history building early-stage teams and driving innovation from skunkwork territory through to battle-tested production systems,” said Heather Leigh Flannery, Founder and Chief Executive Officer, ConsenSys Health. “He is a recognized leader in the blockchain space, and will now bring his leadership to advancing technology in the healthcare and life sciences space.”
Mr. Gleim is a veteran of building successful companies centered on cryptography, machine learning and blockchain technologies. He helped form ConsenSys Diligence (smart contract security) and PegaSys (enterprise-grade blockchain software), each playing an important role in the Ethereum ecosystem. He helped launch the Enterprise Ethereum Alliance, a collection of Fortune 500 and early-stage innovation companies driving the adoption of Ethereum into enterprise operations. Prior to the birth of the Ethereum network, Mr. Gleim co-founded the world’s first blockchain analytics firm, Coinalytics, which currently operates as a component of the Bloq blockchain-for-enterprise offering.
Mr. Gleim spent more than a decade creating intellectual property and best-in-class security products at Motorola and Google and created Google’s first production-gating black-hat security analysis team for embedded systems. He holds a Master of Science degree in Computer Science with a specialization in machine learning from University of Colorado, Boulder and a Bachelor of Science in Cognitive Science from University of California, San Diego. Prior to pursuing his graduate degree, Mr. Gleim performed neuroscience research at the Salk Institute, the Center for Research in Language at UC San Diego, and Rady Children’s Hospital San Diego.